Literature DB >> 26051335

Mapping the location of peritoneal metastases using the peritoneal cancer index and the correlation with overall survival: a retrospective study.

John Spiliotis1, Evgenia E Halkia, Nausika Kalantzi, Stylianos Giassas, Evangelos Lianos, Elias Efstathiou, Paul H Sugarbaker.   

Abstract

PURPOSE: Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) is a promising treatment for patients with peritoneal carcinomatosis (PC). Our objective was to identify new prognostic factors within the Peritoneal Cancer Index (PCI) score in PC patients.
METHODS: 140 patients (60 ovarian, 45 colon, 14 gastric, 10 pseudomyxoma peritonei, 5 mesothelioma, 6 sarcoma) with PC treated with CRS+HIPEC from 2007 to December 2013 were retrospectively included. Tumor extent and location were assessed by the PCI and residual disease was recorded using the Completeness of Cytoreduction (CC) score. All clinical data were computed in univariate and multivariate analysis using survival as primary endpoint.
RESULTS: The PCI remains the most important factor concerning the long-term survival. Involved areas 4, 5 and 8 are more favorable in survival vs areas 9, 10 and 11, which predict a significantly worse outcome (p<0.002). Prognosis varies not only depending on how many peritoneal areas are involved but also on the location of the primary tumor.
CONCLUSION: We demonstrated that the involvement of different areas in the PCI system has a significant impact on the final prognosis and survival.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26051335

Source DB:  PubMed          Journal:  J BUON        ISSN: 1107-0625            Impact factor:   2.533


  3 in total

1.  Readmissions After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy: a US HIPEC Collaborative Study.

Authors:  Tiffany C Lee; Koffi Wima; Jeffrey J Sussman; Syed A Ahmad; Jordan M Cloyd; Ahmed Ahmed; Keith Fournier; Andrew J Lee; Sean Dineen; Benjamin Powers; Jula Veerapong; Joel M Baumgartner; Callisia Clarke; Harveshp Mogal; Mohammad Y Zaidi; Shishir K Maithel; Jennifer Leiting; Travis Grotz; Laura Lambert; Ryan J Hendrix; Daniel E Abbott; Courtney Pokrzywa; Andrew M Blakely; Byrne Lee; Fabian M Johnston; Jonathan Greer; Sameer H Patel
Journal:  J Gastrointest Surg       Date:  2019-11-19       Impact factor: 3.452

2.  Intravenous and intraperitoneal paclitaxel with S-1 for treatment of refractory pancreatic cancer with malignant ascites.

Authors:  Naminatsu Takahara; Hiroyuki Isayama; Yousuke Nakai; Hironori Ishigami; Sohei Satoi; Suguru Mizuno; Hirofumi Kogure; Saburo Matsubara; Natsuyo Yamamoto; Hironori Yamaguchi; Minoru Tada; Joji Kitayama; Toshiaki Watanabe; Kazuhiko Koike
Journal:  Invest New Drugs       Date:  2016-06-23       Impact factor: 3.850

3.  Prognostic Significance of Log(CA125)/PCI for the Resectability of Epithelial Ovarian Cancer: A Retrospective Study.

Authors:  Can He; Niresh Thapa; Yang Wang; Ziye Song; Jing Yang; Mengfei Xu; Na Zuo; Hongbing Cai
Journal:  Cancer Manag Res       Date:  2020-03-25       Impact factor: 3.989

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.